Demonstrated safety and tolerability profile1

Not actual patients.

    Study 1 Adverse Events1

     

    Participants (%) aged 10 to 25 years reporting solicited local and systemic adverse reactions within 7 days of PENMENVY, BEXSERO (Meningococcal Group B Vaccine) or MENVEO [Meningococcal (Groups A, C, Y, and W-135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine] by dose  

     
    PENMENVY
    BEXSERO
    MENVEO
    Dose 1
    Dose 2
    Dose 1
    Dose 2
    Dose 1
    Solicited reactiona
    N = 1638
    N = 1428
    N = 894
    N = 759
    N = 178
    Local adverse reaction
    Pain
    		 Any 92% 88% 92% 89% 38%
    Severe 6% 7% 6% 8% 0%
    Erythema
    		 Any 13% 12% 10% 12% 6%
    Severe 1% 2% 1% 1% 1%
    Swelling
    		 Any 13% 12% 10% 11% 6%
    Severe 2% 2% 1% 2% 1%
    Induration
    		 Any 9% 8% 7% 8% 4%
    Severe 1% 1% 2% 1% 0%
     Systemic adverse reaction
    Fatigue
    		 Any 51% 42% 46% 45% 44%
    Severe 3% 3% 1% 3% 2%
    Nausea
    		 Any 15% 10% 12% 11% 15%
    Severe 0.3% 0.3% 1% 0.4% 1%
    Myalgia
    		 Any 15% 12% 12% 14% 7%
    Severe 1% 1% 1% 0.4% 0%
    Arthralgia
    		 Any 8% 7% 8% 7% 10%
    Severe 1% 0.4% 0.3% 0% 0%
    Headache
    		 Any 42% 36% 37% 37% 39%
    Severe 2% 1% 1% 1% 2%
    Fever
    		 Any 3% 2% 2% 3% 2%
    Severe 0.1% 0.1% 0.1% 0% 1%
    PENMENVY
    Dose 1
    Dose 2
    Solicited reactiona
    N = 1638
    N = 1428
    Local adverse reaction
    Pain
    		 Any 92% 88%
    Severe 6% 7%
    Erythema
    		 Any 13% 12%
    Severe 1% 2%
    Swelling
    		 Any 13% 12%
    Severe 2% 2%
    Induration
    		 Any 9% 8%
    Severe 1% 1%
    Systemic adverse reaction
    Fatigue
    		 Any 51% 42%
    Severe 3% 3%
    Nausea
    		 Any 15% 10%
    Severe 0.3% 0.3%
    Myalgia
    		 Any 15% 12%
    Severe 1% 1%
    Arthralgia
    		 Any 8% 7%
    Severe 1% 0.4%
    Headache
    		 Any 42% 36%
    Severe 2% 1%
    Fever
    		 Any 3% 2%
    Severe 0.1% 0.1%
    BEXSERO
    Dose 1
    Dose 2
    Solicited reactiona
    N = 894
    N = 759
    Local adverse reaction
    Pain
    		 Any 92% 89%
    Severe 6% 8%
    Erythema
    		 Any 10% 12%
    Severe 1% 1%
    Swelling
    		 Any 10% 11%
    Severe 1% 2%
    Induration
    		 Any 7% 8%
    Severe 2% 1%
    Systemic adverse reaction
    Fatigue
    		 Any 46% 45%
    Severe 1% 3%
    Nausea
    		 Any 12% 11%
    Severe 1% 0.4%
    Myalgia
    		 Any 12% 14%
    Severe 1% 0.4%
    Arthralgia
    		 Any 8% 7%
    Severe 0.3% 0%
    Headache
    		 Any 37% 37%
    Severe 1% 1%
    Fever
    		 Any 2% 3%
    Severe 0.1% 0%
    MENVEO
    Dose 1
    Solicited reactiona
    N = 178
    Local adverse reaction
    Pain
    		 Any 38%
    Severe 0%
    Erythema
    		 Any 6%
    Severe 1%
    Swelling
    		 Any 6%
    Severe 1%
    Induration
    		 Any 4%
    Severe 0%
    Systemic adverse reaction
    Fatigue
    		 Any 44%
    Severe 2%
    Nausea
    		 Any 15%
    Severe 1%
    Myalgia
    		 Any 7%
    Severe 0%
    Arthralgia
    		 Any 10%
    Severe 0%
    Headache
    		 Any 39%
    Severe 2%
    Fever
    		 Any 2%
    Severe 1%
    • a

      Erythema, swelling, and induration: Any (≥25 mm); Severe (>100 mm). Pain, fatigue, nausea, myalgia, arthralgia, headache: Any includes Mild (transient with no limitation in normal daily activity), Moderate (some limitation in normal daily activity), and Severe (unable to perform normal daily activity). Fever: Any (≥38.0°C/100.4°F); Severe (≥40.0°C/104.0°F).

    In Study 1, serious adverse events that occurred through 12 months following the first vaccination and at least 5 months following the last vaccination were reported by 1.5% of participants in the PENMENVY group (N=1648), 2.4% of participants in the group who received BEXSERO as a 0-, 6-month schedule with a dose of MENVEO at month 2 (N=900), and 2.8% of participants in the group who received MENVEO at month 0 and BEXSERO at months 6 and 7 (N=178).

      Study 2 Adverse Events1
       

      Percentage of participants aged 15 through 25 years reporting solicited local and systemic adverse reaction within 7 days of PENMENVY or MENVEO, by dose in Study 2

       
      PENMENVY
      MENVEO
      Dose 1
      Dose 2
      Dose 1
      Solicited reactiona
      N = 608
      N = 505-507
      N = 600-601
      Local adverse reaction
      Pain
      		 Any 80% 74% 32%
      Severe 3% 3% 0.3%
      Erythema
      		 Any 5% 6% 2%
      Severe 0.5% 0.6% 0%
      Swelling
      		 Any 4% 6% 2%
      Severe 0.3% 0.6% 0.3%
      Induration
      		 Any 4% 5% 2%
      Severe 2% 0.6% 0.2%
       Systemic adverse reaction
      Fatigue
      		 Any 40% 33% 37%
      Severe 1% 2% 0.5%
      Nausea
      		 Any 15% 12% 13%
      Severe 0.5% 1% 0.7%
      Myalgia
      		 Any 15% 13% 11%
      Severe 0.2% 0.4% 0.3%
      Arthralgia
      		 Any 7% 6% 8%
      Severe 0% 0.2% 0%
      Headache
      		 Any 41% 33% 35%
      Severe 1% 1% 0.7%
      Fever
      		 Any 2% 2% 1%
      Severe 0.2% 0.4% 0.2%
      PENMENVY
      Dose 1
      Dose 2
      Solicited reactiona
      N = 608
      N = 505-507
      Local adverse reaction
      Pain
      		 Any 80% 74%
      Severe 3% 3%
      Erythema
      		 Any 5% 6%
      Severe 0.5% 0.6%
      Swelling
      		 Any 4% 6%
      Severe 0.3% 0.6%
      Induration
      		 Any 4% 5%
      Severe 2% 0.6%
      Systemic adverse reaction
      Fatigue
      		 Any 40% 33%
      Severe 1% 2%
      Nausea
      		 Any 15% 12%
      Severe 0.5% 1%
      Myalgia
      		 Any 15% 13%
      Severe 0.2% 0.4%
      Arthralgia
      		 Any 7% 6%
      Severe 0% 0.2%
      Headache
      		 Any 41% 33%
      Severe 1% 1%
      Fever
      		 Any 2% 2%
      Severe 0.2% 0.4%
      MENVEO
      Dose 1
      Solicited reactiona
      N = 600-601
      Local adverse reaction
      Pain
      		 Any 32%
      Severe 0.3%
      Erythema
      		 Any 2%
      Severe 0%
      Swelling
      		 Any 2%
      Severe 0.3%
      Induration
      		 Any 2%
      Severe 0.2%
      Systemic adverse reaction
      Fatigue
      		 Any 37%
      Severe 0.5%
      Nausea
      		 Any 13%
      Severe 0.7%
      Myalgia
      		 Any 11%
      Severe 0.3%
      Arthralgia
      		 Any 8%
      Severe 0%
      Headache
      		 Any 35%
      Severe 0.7%
      Fever
      		 Any 1%
      Severe 0.2%
      • a

        Erythema, swelling, and induration: Any (≥25 mm); Severe (>100 mm). Pain, fatigue, nausea, myalgia, arthralgia, headache: Any includes Mild (transient with no limitation in normal daily activity), Moderate (some limitation in normal daily activity), and Severe (unable to perform normal daily activity). Fever: Any (≥38.0°C/100.4°F); Severe (≥40.0°C/104.0°F).

      In Study 2, serious adverse events that occurred through 12 months following the first vaccination and at least 5 months following the last vaccination were reported by 2.9% of participants in the PENMENVY group (N=626) and 1.1% of participants in the group who received MENVEO at month 0 and BEXSERO at months 6 and 7 (N=621).

        MenACWY=meningococcal serogroups A, C, W, Y; MenB=meningococcal serogroup B. 

        Indication & Important Safety Info

        Indications for PENMENVY, BEXSERO, and MENVEO

        Important Safety Information for PENMENVY, BEXSERO, and MENVEO

        Indications for PENMENVY, BEXSERO, and MENVEO

        See full Indications and Important Safety Information below.

         

        PENMENVY is a vaccine indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroups A, B, C, W, and Y in individuals 10 through 25 years of age.

        BEXSERO is a vaccine indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B. BEXSERO is approved for use in individuals aged 10 through 25 years.

        MENVEO is a vaccine indicated for active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135 in individuals 2 months through 55 years of age. MENVEO does not prevent N. meningitidis serogroup B infections.

        Important Safety Information for PENMENVY, BEXSERO, and MENVEO

        • Do not administer PENMENVY to individuals with a severe allergic reaction (e.g., anaphylaxis) to a previous dose of PENMENVY, to any component of this vaccine, or to any other diphtheria toxoid-containing vaccine
        • Do not administer BEXSERO to individuals with a history of a severe allergic reaction (e.g., anaphylaxis) to any component of BEXSERO or after a previous dose of BEXSERO
        • Do not administer MENVEO to individuals with a severe allergic reaction (e.g., anaphylaxis) to a previous dose of MENVEO, to any component of MENVEO, or to any other diphtheria toxoid-containing vaccine
        • Appropriate medical treatment must be immediately available to manage potential anaphylactic reactions following administration of PENMENVY, BEXSERO, or MENVEO
        • For BEXSERO, the tip cap of the prefilled syringe may or may not be made with natural rubber latex. Natural rubber latex may cause allergic reactions. Please check the carton
        • Syncope (fainting) has occurred in association with administration of PENMENVY, BEXSERO, or MENVEO. Ensure procedures are in place to avoid injury from falling associated with syncope
        • PENMENVY, BEXSERO, or MENVEO may not protect all vaccine recipients, and PENMENVY or BEXSERO may not protect against all meningococcal serogroup B strains
        • Immunocompromised persons and some individuals receiving immunosuppressant therapy may have reduced immune responses to PENMENVY, BEXSERO, or MENVEO
        • Individuals with certain complement deficiencies and individuals receiving treatment that inhibits terminal complement activation (for example, eculizumab) are at increased risk for invasive disease caused by N. meningitidis serogroups A, B, C, W, and Y, even if they develop antibodies following vaccination with PENMENVY, BEXSERO, or MENVEO
        • Guillain-Barré syndrome (GBS) has been reported in temporal relationship following administration of another US-licensed meningococcal quadrivalent polysaccharide conjugate vaccine. The decision to administer PENMENVY or MENVEO to individuals with a history of GBS should take into account the expected benefits and potential risks
        • Apnea following intramuscular vaccination has been observed in some infants born prematurely. A decision about when to administer MENVEO to an infant born prematurely should be based on consideration of the individual infant’s medical status and the potential benefits and possible risks of vaccination
        • For PENMENVY, the most commonly reported (≥10%) solicited adverse reactions in individuals aged 10 through 25 years after Dose 1 and Dose 2, respectively, were pain at the injection site (92% and 88%), fatigue (51% and 42%), headache (42% and 36%), myalgia (15% and 12%), nausea (15% and 10%), erythema (13% and 12%), and swelling (13% and 12%). The most commonly reported (≥10%) solicited adverse reactions in MenACWY conjugate vaccine-experienced individuals aged 15 through 25 years after Dose 1 and Dose 2, respectively, were pain at the injection site (80% and 74%), headache (41% and 33%), fatigue (40% and 33%), myalgia (15% and 13%), and nausea (15% and 12%)
        • For BEXSERO, the most commonly reported (≥10%) solicited adverse reactions in a Phase 3 clinical trial were pain at the injection site (87%-92%), fatigue (45%-49%), headache (37%-41%), nausea (11%-13%), erythema (10%-15%), myalgia (10%-14%), and swelling (10%-14%)
        • Common solicited adverse reactions with MENVEO among children initiating vaccination: at 2 months of age and receiving the four-dose series were tenderness and erythema at injection site, irritability, sleepiness, persistent crying, change in eating habits, vomiting, and diarrhea; at 7 months through 23 months of age and receiving the two-dose series were tenderness and erythema at injection site, irritability, sleepiness, persistent crying, change in eating habits, and diarrhea; at 2 through 10 years of age who received MENVEO were injection site pain, erythema, irritability, induration, sleepiness, malaise, and headache. Common solicited adverse reactions among adolescents and adults aged 11 through 55 years who received a single dose of MENVEO were pain at the injection site, headache, myalgia, malaise, and nausea. Across all age groups, some events were severe. Similar rates of solicited adverse reactions among adolescents and adults were observed following a single booster dose
        • For MENVEO, in two clinical studies, there were no notable differences in frequency and severity of solicited adverse reactions in individuals who received MENVEO 1-vial presentation compared to individuals who received the 2-vial presentation

         

        Prescribing Information for PENMENVY (Meningococcal Groups A, B, C, W, and Y Vaccine)

         

        Prescribing Information for BEXSERO (Meningococcal Group B Vaccine)

         

        Prescribing Information for MENVEO [Meningococcal (Groups A, C, Y, and W-135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine]

        To report SUSPECTED ADVERSE REACTIONS, contact GSK at gsk.public.reportum.com or
        1-888-825-5249, or VAERS at 1-800-822-7967 or www.vaers.hhs.gov.

        References

        1. Prescribing Information for PENMENVY.